EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Correlation Between iXip and Final Pathology in Patients Affected by Prostate Cancer Undergoing Radical Prostatectomy: A Multicenter Prospective Trial (PROXIMA—PROstate iXip Index Multicenter Analysis)

Simone Francavilla, Chiara Lonati, Marco Sandri, Andrea Abate, Enrico De Marzo, Carlotta Palumbo, Lucia Aretano, Stefano Belotti, Angelo Peroni, Alessandro Peviani, Stefania Ferretti, Luigi Filippo Da Pozzo, Marco Roscigno, Stefano Calza, Agostino Guerini, Sandra Sigala, Claudio Simeone, Alessandro Antonelli

Frontiers in Urology · 2022

DOI: 10.3389/fruro.2021.796688 ↗
AbstractBibliografische Angaben

Abstract

Introduction The Immune compleX Predictive Index (iXip) is a predictive tool for prostate cancer (PCa) diagnosis that integrates PSA, PSA-IgM, prostate volume, and patient age. The aim of the study was to assess the correlation between iXip and clinically significant PCa in patients who underwent radical prostatectomy. Material and Methods A prospective multicenter study was conducted from February 2018 to August 2019 enrolling 235 patients. Stepwise-selected predictors were used to estimate multivariate regression models for each outcome, the reference model with only the set of predictors and the same model with the addition of iXip. The prediction accuracy of the two models was assessed calculating the partial area under the receiver operating characteristic curve. Results The ROC curve analysis showed significant differences in terms of partial area under the curve between iXip and pathological Gleason Score ≥ 7 and between iXip and tumor volume ≥ 2.5 mm 3 . The scatter plot analysis showed a positive linear correlation between iXip and tumor volume (considered as a continuous variable). The subpopulations with pT3–4 disease and cT3 disease and with positive surgical margins showed a significant linear relationship between iXip and tumor volume. Conclusion We found elements supporting a possible correlation between iXip and aggressive PCa in terms of Gleason Score ≥ 7 and tumor volume ≥ 2.5 mm 3 .

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →